Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Accumulated Depreciation (2020)

Vistagen Therapeutics (VTGN) has disclosed Accumulated Depreciation for 3 consecutive years, with $1.0 million as the latest value for Q1 2020.

  • Quarterly Accumulated Depreciation changed N/A to $1.0 million in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Mar 2020, changed N/A year-over-year, with the annual reading at $1.0 million for FY2020, N/A changed from the prior year.
  • Accumulated Depreciation hit $1.0 million in Q1 2020 for Vistagen Therapeutics, up from $711000.0 in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $1.0 million in Q1 2020 to a low of $711000.0 in Q1 2016.